Orchard Therapeutics
London
About Orchard Therapeutics
Orchard Therapeutics is a fully integrated commercial-stage company dedicated to treating the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott-Aldrich syndrome), and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: $10K – $50K
- Total funding: $494.5M
- Funding stage: M&A
- Last round: Post-IPO Equity (Mar 2023)
- Ticker: nasdaq:ORTX
- Website: orchard-tx.com
- Phone: +44 (0) 203 384 6700
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics
Social Profiles
Canonical: https://fsome.com/organization/orchard-therapeutics-24101 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.